Lilly trial shows weight loss with experimental pill flattens over time

Eli Lilly's experimental GLP-1 pill helped people lose about 12 percent of their body weight, with weight loss plateauing for most patients in the 72-week trial, according to full study results presented at a medical meeting on Tuesday. Lilly had announced in August that the Phase 3 study of the daily pill, orforglipron, met its main goals, but the weight loss was less robust than previous trial results for Novo Nordisk's weekly injectable GLP-1 drug Wegovy. That news sent Lilly's shares down 14 percent. Year-to-date, the company's shares have fallen about 1 percent. Results from a late-stage study of the drug orforglipron were presented at a European medical meeting and published in the New England Journal of Medicine. The trial...